Literature DB >> 18615109

Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum.

E Gyan1, E Frisan, O Beyne-Rauzy, J-C Deschemin, C Pierre-Eugene, C Randriamampita, A Dubart-Kupperschmitt, C Garrido, F Dreyfus, P Mayeux, C Lacombe, E Solary, M Fontenay.   

Abstract

Spontaneous apoptosis of bone marrow erythroid precursors accounts for the anemia that characterizes most low-grade myelodysplastic syndromes (MDS). We have shown that death of these precursors involved the Fas-dependent activation of caspase-8. To explore the pathway leading from caspase-8 activation to apoptosis, we transduced MDS bone marrow CD34(+) cells with a lentivirus encoding wild-type (WT) or endoplasmic reticulum (ER)-targeted Bcl-2 protein before inducing their erythroid differentiation. Both WT-Bcl-2 and ER-targeted Bcl-2 prevented spontaneous and Fas-dependent apoptosis in MDS erythroid precursors. ER-targeted Bcl-2 inhibited mitochondrial membrane depolarization and cytochrome c release in MDS erythroid precursors undergoing apoptosis, indicating a role for the ER in the death pathway, upstream of the mitochondria. MDS erythroid precursors demonstrated elevated ER Ca(2+) stores and these stores remained unaffected by ER-targeted Bcl-2. The ER-associated protein Bcl-2-associated protein (BAP) 31 was cleaved by caspase-8 in MDS erythroid precursors undergoing apoptosis. The protective effect of ER-targeted Bcl-2 toward spontaneous and Fas-induced apoptosis correlated with inhibition of BAP31 cleavage. A protective effect of erythropoietin against Fas-induced BAP31 cleavage and apoptosis was observed. We propose that apoptosis of MDS erythroid precursors involves the ER, downstream of Fas and upstream of the mitochondria, through the cleavage of the ER-associated BAP31 protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18615109     DOI: 10.1038/leu.2008.172

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Authors:  Sabrina Bondu; Anne-Sophie Alary; Carine Lefèvre; Alexandre Houy; Grace Jung; Thibaud Lefebvre; David Rombaut; Ismael Boussaid; Abderrahmane Bousta; François Guillonneau; Prunelle Perrier; Samar Alsafadi; Michel Wassef; Raphaël Margueron; Alice Rousseau; Nathalie Droin; Nicolas Cagnard; Sophie Kaltenbach; Susann Winter; Anne-Sophie Kubasch; Didier Bouscary; Valeria Santini; Andrea Toma; Mathilde Hunault; Aspasia Stamatoullas; Emmanuel Gyan; Thomas Cluzeau; Uwe Platzbecker; Lionel Adès; Hervé Puy; Marc-Henri Stern; Zoubida Karim; Patrick Mayeux; Elizabeta Nemeth; Sophie Park; Tomas Ganz; Léon Kautz; Olivier Kosmider; Michaëla Fontenay
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

Review 2.  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Authors:  Kathryn S Ivy; P Brent Ferrell
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

3.  Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.

Authors:  Christopher I Slape; Jesslyn Saw; Jeremy B M Jowett; Peter D Aplan; Andreas Strasser; Stephen M Jane; David J Curtis
Journal:  Blood       Date:  2012-07-31       Impact factor: 22.113

Review 4.  Implication of microRNAs in the pathogenesis of MDS.

Authors:  Jing Fang; Melinda Varney; Daniel T Starczynowski
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Authors:  Anna Raimbault; Cecile Pierre-Eugene; Alexandra Rouquette; Celine Deudon; Lise Willems; Nicolas Chapuis; Stephanie Mathis; Claudia Kunz; Harald Fricke; Olivier Kosmider; Valerie Bardet; Michaela Fontenay
Journal:  Oncotarget       Date:  2016-03-22

6.  Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.

Authors:  Aleksandar Radujkovic; Tobias Boch; Florian Nolte; Daniel Nowak; Claudia Kunz; Alexandra Gieffers; Carsten Müller-Tidow; Peter Dreger; Wolf-Karsten Hofmann; Thomas Luft
Journal:  Cancers (Basel)       Date:  2020-12-08       Impact factor: 6.639

Review 7.  Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?

Authors:  Bruno Fattizzo; Fabio Serpenti; Wilma Barcellini; Chiara Caprioli
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

8.  BAP31 Promotes Proliferation, Invasion, and Metastasis of Liver Cancer Cells via Activating PI3K/AKT Pathway.

Authors:  Minmin Sun; Xue Liu; Wanying Wei; Naijian Ge; Shuli Luo; Shuqun Shen; Ruiliang Ge
Journal:  J Healthc Eng       Date:  2022-04-11       Impact factor: 3.822

9.  Immunological derangement in hypocellular myelodysplastic syndromes.

Authors:  B Serio; Am Risitano; V Giudice; N Montuori; C Selleri
Journal:  Transl Med UniSa       Date:  2014-02-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.